Axalta Coating Systems Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Axalta Coating Systems Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.28B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.18B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.88B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $4.42B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $1.07B | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $1.03B | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $652.70M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $983.50M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $1.10B | Feb 18, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.28B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $5.18B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.88B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $4.42B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $3.74B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $4.48B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $4.70B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $4.38B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $4.07B | Feb 26, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.35B | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $4.07B | Feb 22, 2018 |
| FY2017 | Dec 31, 2015 | $4.08B | Feb 22, 2018 |
| FY2016 | Dec 31, 2014 | $4.36B | Feb 28, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $378.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $391.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $267.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $192.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $263.90M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $69.70M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $82.50M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | ($82.80M) | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $52.20M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $41.70M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $735.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $706.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $588.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $423.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $462.40M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $163.20M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $141.70M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | ($64.50M) | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $65.10M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $108.70M | Feb 18, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $74.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $74.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $66.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $62.40M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $55.20M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $70.20M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $73.10M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $65.30M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $57.70M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $805.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $847.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $840.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $772.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $738.70M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $695.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $822.10M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $876.40M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $934.70M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $959.80M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $649.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $576.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $575.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $294.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $558.60M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $509.30M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $573.10M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $496.10M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $540.00M | Feb 19, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $140.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $138.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $151.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $121.60M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $82.10M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $112.50M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $143.40M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $125.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $136.20M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.60B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $7.25B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.27B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $7.06B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.22B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $7.16B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $6.82B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $6.68B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $6.83B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $5.87B | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.21B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.29B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $5.50B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $5.56B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.68B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $5.68B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $5.41B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $5.37B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.42B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.62B | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.35B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.91B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.73B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.45B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.49B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.43B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.35B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.21B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.28B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.13B | Feb 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.64B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.59B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.50B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.59B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.29B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.21B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $1.23B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $1.27B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $964.10M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.06B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.68B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.29B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.02B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $827.20M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $563.30M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $443.20M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $198.60M | Feb 19, 2020 |
| FY2018 | Jan 1, 2018 | ($9.30M) | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | ($21.40M) | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $657.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $593.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $700.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $645.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $840.60M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.36B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.02B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $693.60M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $769.80M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $535.40M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.86B | Feb 18, 2022 |
| FY2019 | Dec 31, 2019 | $3.88B | Feb 19, 2020 |
| FY2018 | Dec 31, 2018 | $3.89B | Feb 26, 2019 |
| FY2017 | Dec 31, 2017 | $3.95B | Feb 22, 2018 |
| FY2016 | Dec 31, 2016 | $3.30B | Feb 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 251.80M | Feb 18, 2022 |
| FY2021 | Dec 31, 2020 | 250.90M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 250.10M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 246.70M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 243.90M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 240.50M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | 237.90M | Feb 28, 2017 |